178 related articles for article (PubMed ID: 23689710)
21. Relative replicative fitness of human immunodeficiency virus type 1 mutants resistant to enfuvirtide (T-20).
Lu J; Sista P; Giguel F; Greenberg M; Kuritzkes DR
J Virol; 2004 May; 78(9):4628-37. PubMed ID: 15078945
[TBL] [Abstract][Full Text] [Related]
22. Mutations conferring resistance to human immunodeficiency virus type 1 fusion inhibitors are restricted by gp41 and Rev-responsive element functions.
Nameki D; Kodama E; Ikeuchi M; Mabuchi N; Otaka A; Tamamura H; Ohno M; Fujii N; Matsuoka M
J Virol; 2005 Jan; 79(2):764-70. PubMed ID: 15613304
[TBL] [Abstract][Full Text] [Related]
23. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
24. Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy.
Zhu X; Zhu Y; Ye S; Wang Q; Xu W; Su S; Sun Z; Yu F; Liu Q; Wang C; Zhang T; Zhang Z; Zhang X; Xu J; Du L; Liu K; Lu L; Zhang R; Jiang S
Sci Rep; 2015 Aug; 5():13028. PubMed ID: 26286358
[TBL] [Abstract][Full Text] [Related]
25. Transmembrane protein polymorphisms and resistance to T-20 (Enfuvirtide, Fuzeon) in HIV-1 infected therapy-naive seroconverters and AIDS patients under HAART-T-20 therapy.
Morozov VA; Morozov AV; Schürmann D; Jessen H; Kücherer C
Virus Genes; 2007 Oct; 35(2):167-74. PubMed ID: 17440804
[TBL] [Abstract][Full Text] [Related]
26. Effect of naturally-occurring gp41 HR1 variations on susceptibility of HIV-1 to fusion inhibitors.
Chinnadurai R; Münch J; Kirchhoff F
AIDS; 2005 Sep; 19(13):1401-5. PubMed ID: 16103771
[TBL] [Abstract][Full Text] [Related]
27. Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy.
Poveda E; Rodés B; Lebel-Binay S; Faudon JL; Jimenez V; Soriano V
J Clin Virol; 2005 Dec; 34(4):295-301. PubMed ID: 16286053
[TBL] [Abstract][Full Text] [Related]
28. HIV-1 gp41 heptad repeat 2 (HR2) possesses an amino acid domain that resembles the allergen domain in Aspergillus fumigatus Asp f1 protein: review, hypothesis and implications.
Becker Y
Virus Genes; 2007 Jun; 34(3):233-40. PubMed ID: 17333401
[TBL] [Abstract][Full Text] [Related]
29. Are fusion inhibitors active against all HIV variants?
Poveda E; Rodes B; Toro C; Soriano V
AIDS Res Hum Retroviruses; 2004 Mar; 20(3):347-8. PubMed ID: 15117459
[TBL] [Abstract][Full Text] [Related]
30. Impact of the HIV-1 env genetic context outside HR1-HR2 on resistance to the fusion inhibitor enfuvirtide and viral infectivity in clinical isolates.
Baatz F; Nijhuis M; Lemaire M; Riedijk M; Wensing AM; Servais JY; van Ham PM; Hoepelman AI; Koopmans PP; Sprenger HG; Devaux C; Schmit JC; Perez Bercoff D
PLoS One; 2011; 6(7):e21535. PubMed ID: 21760896
[TBL] [Abstract][Full Text] [Related]
31. In vitro generation of HIV type 1 subtype C isolates resistant to enfuvirtide.
Cilliers T; Moore P; Coetzer M; Morris L
AIDS Res Hum Retroviruses; 2005 Sep; 21(9):776-83. PubMed ID: 16218801
[TBL] [Abstract][Full Text] [Related]
32. Treatment with the fusion inhibitor enfuvirtide influences the appearance of mutations in the human immunodeficiency virus type 1 regulatory protein rev.
Svicher V; Alteri C; D'Arrigo R; Laganà A; Trignetti M; Lo Caputo S; Callegaro AP; Maggiolo F; Mazzotta F; Ferro A; Dimonte S; Aquaro S; di Perri G; Bonora S; Tommasi C; Trotta MP; Narciso P; Antinori A; Perno CF; Ceccherini-Silberstein F
Antimicrob Agents Chemother; 2009 Jul; 53(7):2816-23. PubMed ID: 19124665
[TBL] [Abstract][Full Text] [Related]
33. A Helical Short-Peptide Fusion Inhibitor with Highly Potent Activity against Human Immunodeficiency Virus Type 1 (HIV-1), HIV-2, and Simian Immunodeficiency Virus.
Xiong S; Borrego P; Ding X; Zhu Y; Martins A; Chong H; Taveira N; He Y
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795437
[TBL] [Abstract][Full Text] [Related]
34. Synergistic efficacy of combination of enfuvirtide and sifuvirtide, the first- and next-generation HIV-fusion inhibitors.
Pan C; Lu H; Qi Z; Jiang S
AIDS; 2009 Mar; 23(5):639-41. PubMed ID: 19242316
[TBL] [Abstract][Full Text] [Related]
35. Enfuvirtide (T-20) resistance-related mutations in HIV type 1 subtypes B, C, and F isolates from Brazilian patients failing HAART.
Oliveira AC; Martins AN; Pires AF; Arruda MB; Tanuri A; Pereira HS; Brindeiro RM
AIDS Res Hum Retroviruses; 2009 Feb; 25(2):193-8. PubMed ID: 19239358
[TBL] [Abstract][Full Text] [Related]
36. Sphingopeptides: dihydrosphingosine-based fusion inhibitors against wild-type and enfuvirtide-resistant HIV-1.
Ashkenazi A; Viard M; Unger L; Blumenthal R; Shai Y
FASEB J; 2012 Nov; 26(11):4628-36. PubMed ID: 22872679
[TBL] [Abstract][Full Text] [Related]
37. Dynamics of drug-resistant HIV-1 in plasma and peripheral blood cells in patients during and after enfuvirtide therapy.
Poveda E; Briz V; Paraskevis D; Barreiro P; Hatzakis A; Soriano V
AIDS Res Hum Retroviruses; 2007 Sep; 23(9):1078-82. PubMed ID: 17919101
[TBL] [Abstract][Full Text] [Related]
38. Resistance profiles of novel electrostatically constrained HIV-1 fusion inhibitors.
Shimura K; Nameki D; Kajiwara K; Watanabe K; Sakagami Y; Oishi S; Fujii N; Matsuoka M; Sarafianos SG; Kodama EN
J Biol Chem; 2010 Dec; 285(50):39471-80. PubMed ID: 20937812
[TBL] [Abstract][Full Text] [Related]
39. Determinants of human immunodeficiency virus type 1 resistance to membrane-anchored gp41-derived peptides.
Lohrengel S; Hermann F; Hagmann I; Oberwinkler H; Scrivano L; Hoffmann C; von Laer D; Dittmar MT
J Virol; 2005 Aug; 79(16):10237-46. PubMed ID: 16051817
[TBL] [Abstract][Full Text] [Related]
40. Biophysical property and broad anti-HIV activity of albuvirtide, a 3-maleimimidopropionic acid-modified peptide fusion inhibitor.
Chong H; Yao X; Zhang C; Cai L; Cui S; Wang Y; He Y
PLoS One; 2012; 7(3):e32599. PubMed ID: 22403678
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
